N4751
Nicotinuric acid
Synonym(s):
Nicotinylglycine
Sign Into View Organizational & Contract Pricing
About This Item
Empirical Formula (Hill Notation):
C8H8N2O3
CAS Number:
Molecular Weight:
180.16
EC Number:
MDL number:
UNSPSC Code:
12352106
PubChem Substance ID:
NACRES:
NA.79
Assay
≥98% (with NaOH, titration)
form
powder
color
white
SMILES string
OC(=O)CNC(=O)c1cccnc1
InChI
1S/C8H8N2O3/c11-7(12)5-10-8(13)6-2-1-3-9-4-6/h1-4H,5H2,(H,10,13)(H,11,12)
InChI key
ZBSGKPYXQINNGF-UHFFFAOYSA-N
Biochem/physiol Actions
Nicotinuric acid (NUA) is a metabolite of niacin/vitamin B. Measurement of NUA levels in urine is used to indicate possible elevated nicotinamide adenine dinucleotide (NAD) catabolism. NUA may be used as a reference (standard curve) in the analysis of NAD and NUA catabolism. Nicotinic acid reduces triglycerides and increases high density lipoprotein(HDL) cholesterol.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
R H Stern et al.
Clinical pharmacology and therapeutics, 50(1), 66-70 (1991-07-01)
The mechanism of tolerance to nicotinic acid flushing was determined in subjects during a 5-day course of treatment. Objective measures of skin blood flow were used to confirm the development of tolerance. Plasma levels of nicotinic acid showed marked intraindividual
High-performance liquid chromatographic determination of nicotinic acid and its metabolites, nicotinuric acid and nicotinamide, in plasma.
K Takikawa et al.
Journal of chromatography, 233, 343-348 (1982-12-10)
Ines Reiche et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 26(1), 276-282 (2010-06-22)
Niaspan® is an extended-release formulation of nicotinic acid with improved tolerability compared with the immediate-release and sustained-release formulations. It is used to treat hypertriglyceridaemia with low high-density lipoprotein levels. This type of dyslipidaemia frequently appears in patients with chronic kidney
P J Neuvonen et al.
British journal of clinical pharmacology, 32(4), 473-476 (1991-10-01)
1. The bioavailability of three nicotinic acid formulations was investigated in a randomized cross-over study. 2. Single doses of nicotinic acid (500 mg) were given to seven healthy volunteers. The concentrations of nicotinic acid and its main metabolite nicotinuric acid
M Iwaki et al.
Drug metabolism and disposition: the biological fate of chemicals, 24(7), 773-779 (1996-07-01)
The pharmacokinetics of nicotinic acid (NiAc) and nicotinuric acid (NiUAc), the major metabolite of NiAc, and the dose dependency of these pharmacokinetics were determined in rats. Intravenous injections of 2, 5, 15, and 45 mg/kg of NiAc and 5 and
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service